Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2006

01-03-2006

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

Authors: Toshiyuki Sawa, Takashi Yana, Minoru Takada, Takahiko Sugiura, Shinzoh Kudoh, Tadashi Kamei, Takeshi Isobe, Hidehiko Yamamoto, Soichiro Yokota, Nobuyuki Katakami, Yuji Tohda, Akira Kawakami, Yoichi Nakanishi, Yutaka Ariyoshi

Published in: Investigational New Drugs | Issue 2/2006

Login to get access
Metadata
Title
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial
Authors
Toshiyuki Sawa
Takashi Yana
Minoru Takada
Takahiko Sugiura
Shinzoh Kudoh
Tadashi Kamei
Takeshi Isobe
Hidehiko Yamamoto
Soichiro Yokota
Nobuyuki Katakami
Yuji Tohda
Akira Kawakami
Yoichi Nakanishi
Yutaka Ariyoshi
Publication date
01-03-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 2/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-006-5937-2

Other articles of this Issue 2/2006

Investigational New Drugs 2/2006 Go to the issue

OriginalPaper

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

OriginalPaper

A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma

OriginalPaper

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies

OriginalPaper

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

Short Report

Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma

OriginalPaper

Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits